ADHD:
Indications for: STRATTERA
Attention deficit hyperactivity disorder (ADHD).
Adults and Children:
Swallow whole. Give once daily in the AM, or in 2 evenly divided doses (in AM and late afternoon/early PM). <6yrs: not established. Acute: ≥6yrs (≤70kg): initially 0.5mg/kg/day; increase after at least 3 days to 1.2mg/kg/day; max 1.4mg/kg or 100mg/day (whichever is less); (>70kg): initially 40mg/day; increase after at least 3 days to 80mg/day, then after 2–4 weeks may increase to max 100mg/day. Maintenance: 6–15yrs: continue with same dose, reevaluate periodically; see full labeling. Concomitant potent CYP2D6 inhibitors: titrate above initial dose at 4-week intervals only if needed. Hepatic impairment (moderate): reduce dose by 50%; (severe): reduce dose by 75%. May discontinue without tapering.
STRATTERA Contraindications:
During or within 14 days of MAOIs. Narrow angle glaucoma. Pheochromocytoma or history of. Severe cardiovascular disorders that might deteriorate with clinically important increases in HR and BP.
Boxed Warning:
Suicidal ideation in children and adolescents.
STRATTERA Warnings/Precautions:
Increased risk of suicidal ideation in children and adolescents. Monitor closely for clinical worsening, suicidality and unusual changes in behavior (esp. during initial therapy and dose adjustments). Severe liver injury (discontinue if jaundice or elevated liver enzymes occur; do not restart). Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Assess cardiovascular status and do physical exam. Hypertension. Tachycardia. Cardio- or cerebrovascular disease. Psychoses. Screen for bipolar disorder prior to initiation. Depression. Monitor growth, BP/pulse (esp. at baseline and after dose increases), emergence or worsening of aggressive behavior/hostility. Poor metabolizers (CYP2D6). Reevaluate periodically. Elderly. Labor & delivery. Pregnancy. Nursing mothers.
STRATTERA Classification:
Selective norepinephrine reuptake inhibitor.
STRATTERA Interactions:
MAOIs: see Contraindications. May be potentiated by potent CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Increased cardiovascular effects with albuterol, pressor agents (eg, dobutamine, dopamine).
Adverse Reactions:
Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence, weight loss, dizziness, headache, mood swings, tachycardia, hypertension, orthostatic hypotension, mydriasis; rare: severe liver injury, priapism, anaphylaxis. Adults also: constipation, dry mouth, insomnia, sexual dysfunction, urinary retention/hesitation, dysuria, dysmenorrhea, hot flush.
Generic Drug Availability:
YES
How Supplied:
Caps—30
